general info & the event
Are you interested to join the DIH-HERO network, apply for the open calls (to be published soon), and looking for your cross-border partner? Save the date for the Brokerage Event on the 30 & 31 of October, at the University of Twente, The Netherlands.
DIH-HERO will offer a program of cross-border matchmaking between companies and with end users by workshops and face-to-face meetings. We will inform about the calls, services and open infrastructures (such as living labs, testbeds etc.) that are available within the DIH-HERO community. Visit the DIH-HERO website here.
WHERE & WHEN
- 30th & 31th of October 2019
- University of Twente, Enschede, The Netherlands (route)
- Language: English
registration & cancelation
We welcome a maximum number of 300 participants. Participation is free of charge. We will count on your participation for reserving a seat and the drinks. If you cannot attend the event for which you have already registered, we kindly ask that you let us know. Simply e-mail email@example.com
Downloads & links:
Our primary objective is to accelerate innovation in robotics for healthcare. To connect innovators, providers, businesses, users and politicians, DIH-HERO will establish an open online portal offering multiple services facilitating collaboration on various innovations, emphasizing the sharing of best practice and enhancing the delivery of innovation throughout the value chain. DIH-HERO especially focuses on supporting small and medium-sized enterprises in maximizing their impact and reducing time-to-market. By connecting businesses and healthcare stakeholders, DIH-HERO enables them to develop innovative products and services that are better fitted to the needs of the healthcare systems across Europe. Furthermore, DIH-HERO will engage in necessary standardization for robotics in healthcare, including ethical, legal and societal issues. More information about the organisation,
This project has received funding from the European Union’s Horizon 2020 research and innovation programm under grant agreement No 825003.